DCR look impressive compared to SoC given how difficult it is to treat Cholangiocarcinoma and the expansion was only announced 12 months ago so these data for the other patients are at most only 9 months after receiving treatment. The CR was the longest on the VAXINIA clinical trial, not sure how long it took for him to achieve CR.
"For most patients, FOLFOX (folinic acid, fluorouracil, and oxaliplatin) is the recommended second-line treatment for CCA. FOLFOX is approved for the treatment of CCA based on results from the ABC-06 study, which demonstrated that FOLFOX achieves an ORR of 5%, a DCR of 33%, and a median overall survival of 6.2 months, highlighting the need for more effective treatment options."
IMU Price at posting:
2.4¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)